We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout
Read MoreHide Full Article
ResMed (RMD - Free Report) recently announced the acquisition of Somnoware — the renowned, privately held, sleep and respiratory care diagnostics software provider in the United States. The partnership will enable innovations and deliver solutions that improve the health of patients with sleep disorders and other chronic respiratory diseases.
The recent development expands ResMed’s sleep management software solution, which will help physicians, sleep labs and HMEs (Home Medical Equipment) drive greater efficiency and deliver better patient care.
News in Detail
Somnoware’s diagnostic management platform naturally complements RMD’s portfolio of digital solutions across the patient care pathway, including the current post-testing AirView and Brightree offerings. The company is committed to broadening the adoption of Somnoware’s open and interoperable platform to help more people with OSA (Obstructive Sleep Apnoea) or COPD (Chronic Obstructive Pulmonary Disease) get the diagnoses and treatment solutions they need.
Image Source: Zacks Investment Research
The software streamlines the processes of physicians, and sleep and pulmonary function testing labs. These include diagnosing and evaluating a patient’s sleep and respiratory care test results, ordering PAP (Positive Airway Pressure) treatment equipment, setting up appointments, tracking PAP compliance and electronically providing this information directly to a patient’s electronic health record.
Under the agreement, ResMed intends to retain all Somnoware staff and integrate its offerings into the ResMed brand and solution ecosystem. By maintaining the open and device-agnostic nature of Somnoware’s offerings, end users can continue to interoperate with various testing solutions and place orders for treatment devices and accessories from any supplier.
The financial terms of the transaction were not disclosed.
Industry Prospects
Per a Research report, the global sleep apnea devices market was valued at $4.2 billion in 2022 and is expected to witness a CAGR of 6.2% by 2030.
The Potential of Digital Health
ResMed is laser-focused on accelerating the adoption of digital health in sleep apnea, COPD, insomnia, and out-of-hospital care. Following a favorable market launch, the increasing production and global availability of the AirSense 11 device platform remains a top priority for the company.
In the fiscal third quarter of 2023, RMD’s cloud-based patient management system, AirView, registered the highest number of new patient setups. ResMed plans to introduce several AI-driven coaching features in the AirView system and on the patient-facing myAir app in the next several quarters. These AI algorithms will provide personalized suggestions to improve patient experience and ultimately increase patient therapy adherence.
Price Performance
In the past six months, ResMed has mainly underperformed its industry. Shares of the company have increased 2.5% compared with the industry’s rise of 3.0%.
Haemonetics’ stock has risen 23.6% in the past year. The Zacks Consensus Estimate for Haemonetics’ earnings per share (EPS) has increased from $3.55 to $3.56 for fiscal 2024 and remained constant at $3.96 for fiscal 2025 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, the company registered an earnings surprise of 13.24%.
The Zacks Consensus Estimate for Zimmer Biomet’s 2023 EPS has remained constant at $7.45 in the past 30 days. Shares of the company have improved 34% in the past year against the industry’s 22.8% decline.
ZBH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.38%. In the last reported quarter, the company recorded an earnings surprise of 13.86%.
The Zacks Consensus Estimate for SiBone’s 2023 loss per share has narrowed from $1.44 to $1.42 in the past 30 days. SIBN shares have improved 85.9% in the past year compared with the industry’s 9% growth.
SiBone’s earnings beat estimates in three of the trailing four quarters and missed the same in one, the average surprise being 11.11%. In the last reported quarter, the company recorded an earnings surprise of 21.95%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout
ResMed (RMD - Free Report) recently announced the acquisition of Somnoware — the renowned, privately held, sleep and respiratory care diagnostics software provider in the United States. The partnership will enable innovations and deliver solutions that improve the health of patients with sleep disorders and other chronic respiratory diseases.
The recent development expands ResMed’s sleep management software solution, which will help physicians, sleep labs and HMEs (Home Medical Equipment) drive greater efficiency and deliver better patient care.
News in Detail
Somnoware’s diagnostic management platform naturally complements RMD’s portfolio of digital solutions across the patient care pathway, including the current post-testing AirView and Brightree offerings. The company is committed to broadening the adoption of Somnoware’s open and interoperable platform to help more people with OSA (Obstructive Sleep Apnoea) or COPD (Chronic Obstructive Pulmonary Disease) get the diagnoses and treatment solutions they need.
Image Source: Zacks Investment Research
The software streamlines the processes of physicians, and sleep and pulmonary function testing labs. These include diagnosing and evaluating a patient’s sleep and respiratory care test results, ordering PAP (Positive Airway Pressure) treatment equipment, setting up appointments, tracking PAP compliance and electronically providing this information directly to a patient’s electronic health record.
Under the agreement, ResMed intends to retain all Somnoware staff and integrate its offerings into the ResMed brand and solution ecosystem. By maintaining the open and device-agnostic nature of Somnoware’s offerings, end users can continue to interoperate with various testing solutions and place orders for treatment devices and accessories from any supplier.
The financial terms of the transaction were not disclosed.
Industry Prospects
Per a Research report, the global sleep apnea devices market was valued at $4.2 billion in 2022 and is expected to witness a CAGR of 6.2% by 2030.
The Potential of Digital Health
ResMed is laser-focused on accelerating the adoption of digital health in sleep apnea, COPD, insomnia, and out-of-hospital care. Following a favorable market launch, the increasing production and global availability of the AirSense 11 device platform remains a top priority for the company.
In the fiscal third quarter of 2023, RMD’s cloud-based patient management system, AirView, registered the highest number of new patient setups. ResMed plans to introduce several AI-driven coaching features in the AirView system and on the patient-facing myAir app in the next several quarters. These AI algorithms will provide personalized suggestions to improve patient experience and ultimately increase patient therapy adherence.
Price Performance
In the past six months, ResMed has mainly underperformed its industry. Shares of the company have increased 2.5% compared with the industry’s rise of 3.0%.
Zacks Rank and Key Picks
ResMed currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector are Haemonetics (HAE - Free Report) , Zimmer Biomet (ZBH - Free Report) and SiBone (SIBN - Free Report) . While Haemonetics sports a Zacks Rank #1 (Strong Buy), Zimmer Biomet and SiBone each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has risen 23.6% in the past year. The Zacks Consensus Estimate for Haemonetics’ earnings per share (EPS) has increased from $3.55 to $3.56 for fiscal 2024 and remained constant at $3.96 for fiscal 2025 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, the company registered an earnings surprise of 13.24%.
The Zacks Consensus Estimate for Zimmer Biomet’s 2023 EPS has remained constant at $7.45 in the past 30 days. Shares of the company have improved 34% in the past year against the industry’s 22.8% decline.
ZBH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.38%. In the last reported quarter, the company recorded an earnings surprise of 13.86%.
The Zacks Consensus Estimate for SiBone’s 2023 loss per share has narrowed from $1.44 to $1.42 in the past 30 days. SIBN shares have improved 85.9% in the past year compared with the industry’s 9% growth.
SiBone’s earnings beat estimates in three of the trailing four quarters and missed the same in one, the average surprise being 11.11%. In the last reported quarter, the company recorded an earnings surprise of 21.95%.